Biotricity Inc. (BTCY) shareholders
Close on Oct 19, 2026Market cap $1.15MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Ionic Ventures, LLC Joint filing with Ionic Management, LLC (9.90%), Brendan O'Neil (9.90%) and 1 more | 3,241,770 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of BTCY | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Strengthening Families & Communities, LLC | 48,263 | 0.24% | $5.99K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1 | 0M | 0.2% | 0 / 0 | 0 / 1 | 0M | 0M |
| Q1 2026 | 2 | 0M | 0.3% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q4 2025 | 1 | 0M | 0.1% | 1 / 0 | 0 / 1 | 0M | 0M |
| Q3 2025 | 1 | 0M | 0.2% | 1 / 0 | 0 / 0 | 0M | 0M |
| Q4 2024 | 0 | 0M | 0.0% | 0 / 0 | 0 / 4 | 0M | 0M |
| Q3 2024 | 4 | 0M | 0.3% | 1 / 0 | 0 / 16 | 0M | 0M |
| Q2 2024 | 20 | 0M | 2.4% | 6 / 3 | 3 / 2 | 0M | 0M |
| Q1 2024 | 16 | 0M | 1.8% | 1 / 2 | 3 / 5 | 0M | 0M |
| Q4 2023 | 20 | 0M | 1.8% | 3 / 3 | 5 / 4 | 0M | 0M |
| Q3 2023 | 21 | 1M | 2.5% | 21 / 0 | 0 / 0 | 1M | 0M |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Norman M. Betts Director | Nov 29, 2021 | Award | +54,348 | – | – | 375,598 |
| David A. Rosa Director | Nov 29, 2021 | Award | +27,174 | – | – | 152,174 |
| David A. Rosa Director | Oct 11, 2021 | Sale | −3,318 | $3.05 | $10.12K | 125,000 |
| David A. Rosa Director | Oct 8, 2021 | Sale | −9,481 | $3.20 | $30.34K | 128,318 |
| David A. Rosa Director | Oct 7, 2021 | Sale | −17,228 | $3.08 | $53.06K | 137,799 |
| David A. Rosa Director | Sep 16, 2021 | Sale | −34,977 | $3.43 | $119.97K | 155,027 |
| David A. Rosa Director | Sep 15, 2021 | Sale | −6,246 | $3.27 | $20.42K | 190,004 |
| Patricia J. Kennedy Director | Apr 7, 2020 | Award | +125,000 | – | – | 250,000 |
| Norman M. Betts Director | Apr 7, 2020 | Award | +125,000 | – | – | 321,250 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Biotricity's stock actually held short. Settlement fails (shares not delivered on time) peaked at 2,170 shares on Oct 7, 2026 over the last 90 days.
See a number that looks wrong?